Newsletter Subscription

Enter Name and Email

NeuroAct Communication - Newsletter - May 2012


Expertise in Neuropharmacology






Spring News

French Psychiatry meetings

Adrian Newman-Tancredi PhD presented at two psychiatry meetings in Paris, France: at the 10th Encéphale Congress on 19th January and at the AFPBN meeting on 16th March. The symposiums were sponsored by AstraZeneca and focused on the mechanism of action of antipsychotics. More information here and here.

Belgian neuropharmacology lecture tour

Adrian spent a week in Belgium giving lectures to psychiatrists in 5 different psychiatric hospitals and universities. The lectures were sponsored by BMS and described the profiles of action of antipsychotic drugs with particular focus on the role of serotonin 5-HT1A receptors.

Academic contacts

Adrian acted as external examiner for a PhD candidate at the Institut Pierre et Marie Curie on 22nd March. The thesis work, carried out by Dr. Marie-Josèphe Salles, in the laboratory of Prof. Denis Hervé, concerned the signal transduction mechanisms of dopamine D2 and D3 receptors.

For more information on Adrian's lectures and neuropharmacology expertise: Consulting services.















NeuroAct Communication advises lifescience companies and funding agencies on neuropharmacology and central nervous system drug discovery programs.  


NeuroAct Communication is an independent consulting service founded by Adrian Newman-Tancredi Ph.D.,

an experienced pharmaceutical industry professional.
Find out more about Adrian in his Executive Profile



Scientific Communication

Just Published:

In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and post-synaptic 5-HT1A receptors in the rat.

Lladó-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.
Psychopharmacology (Berl). 2012 221(2): 261-272.

To find out more about Adrian's scientific communication, see his Publications






Neurolixis update

Adrian Newman-Tancredi is co-founder and Chief Scientific Officer of Neurolixis Inc., a CNS drug discovery and development start-up.

Neurolixis recently leased laboratory premises at a start-up "incubator" founded by J&J in San Diego. The labs provide a platform for synthesizing novel chemical entities (NCEs) designed to treat serious CNS disorders, including depression, schizophrenia and Parkinson's disease.

Note: Neurolixis is currently aquiring financing from investors and grant-awarding institutions to support its drug discovery and early development projects. For further information or to make an investment, Contact.